NSCLC Molecular Testing Faces Critical Barriers as Targeted Therapies Expand

Non-small cell lung cancer (NSCLC) treatment has undergone a fundamental transformation, evolving from a single disease approach to managing multiple distinct molecular subtypes, each requiring specialized targeted therapies. This shift has created significant challenges for clinicians, particularly in community settings where experience with rare molecular drivers may be limited.

Jorge Nieva, MD, associate professor of clinical medicine at Keck School of Medicine of the University of Southern California, highlighted the growing complexity facing oncologists during a recent Institute for Value-Based Medicine® event. "When it stopped being one disease and started being 10 different diseases with 10 different treatment pathways, knowing the right thing to do has become more difficult for practitioners that see a low volume of patients with these particularly rare diseases," Nieva explained.

Expertise Gap in Rare Molecular Subtypes

The challenge is particularly acute for community oncologists who may encounter certain molecular subtypes infrequently. While academic specialists see diverse NSCLC cases regularly, general oncologists in community practice may have limited exposure to non-smoking-related lung cancers and their associated targeted therapies.

"For my friend who's a general oncologist who practices in North Carolina, he sees a lot of tobacco-related lung cancer and doesn't see a lot of the non-smoking–related lung cancers," Nieva noted. "While he knows that somebody with a ROS1 rearrangement may need some kind of special drug, maybe he's not used any of the drugs for ROS1 rearrangements, or maybe hasn't used them in the last 3 years."

This creates a learning curve where clinicians may be prescribing drugs they have rarely or never used before, potentially impacting patient care quality. The solution, according to Nieva, lies in developing better informatics tools to educate both patients and clinicians about treatment expectations and drug-specific characteristics.

Tissue Adequacy: The Primary Testing Barrier

Despite the critical importance of molecular testing, significant barriers continue to limit timely and comprehensive genomic profiling. Nieva identified tissue adequacy as the number one obstacle, stemming from the inherent challenges of lung cancer diagnosis.

"Lung cancer is one of the most difficult tumor types to get good tissue from," Nieva explained. "It is risky in many ways to put needles into the lungs, because they have a tendency of collapsing, and as a result of that, the majority of lung cancer pathological specimens that we have tend to be small."

The problem is compounded by current community practices, where most patients are diagnosed using transthoracic biopsies obtained through CT guidance. These procedures often utilize 20-gauge or smaller needles for safety reasons, resulting in specimens that are among the smallest available for any tumor type.

Next-generation sequencing, which has become the standard for obtaining genomic information, requires substantial tissue samples—approximately 20 to 25 slides. Research has shown that bronchoscopically obtained tissue tends to be larger with higher success rates for sequencing, but access to interventional pulmonologists who perform these procedures remains limited, particularly in rural areas.

Turnaround Time Challenges

The second major barrier involves the time required for next-generation sequencing results. Current processes take approximately 2 weeks from tissue arrival at the laboratory through amplification, sequencing, bioinformatics analysis, and result reporting.

"For many cancer patients, that 2 weeks is excruciating because you know you have cancer, you know that it's bad, and you don't know what your treatment is going to look like or what your prognosis is going to be until this black box information comes out," Nieva observed.

This delay necessitates the development of faster diagnostic technologies capable of providing quick turnaround results using smaller tissue quantities. While such technologies are under development, they are not yet ready for widespread clinical implementation.

Value of Repeat Testing

Repeat biomarker testing plays an important role in managing treatment resistance, particularly as resistance mutations develop in various lung cancer types. However, the value proposition varies significantly across different molecular subtypes.

"Repeat testing is valuable, because for a subset of patients, it will tell us what the best next treatment is," Nieva explained. "Of course, for a lot of lung cancer types, it's going to have relatively low yield in terms of finding something that's going to be actionable in the second or third line."

The challenge lies in determining the optimal testing frequency while considering cost-effectiveness, particularly for rare resistance mechanisms. As clinical trials may not be feasible for many rare scenarios, real-world evidence will likely play an increasingly important role in guiding testing strategies.

Equity Concerns in Molecular Testing Access

A critical concern emerging in the molecular testing landscape involves ensuring equitable access across different care environments. Nieva emphasized the need to prevent disparities between patients with comprehensive insurance coverage and those receiving care in value-based systems.

"We need to find ways of making sure that those patients who are being treated in value-based systems are not being shortchanged of the most valuable thing that they can have, which is a good understanding of the molecular genomics of their underlying cancer," he stated.

This equity challenge becomes particularly important as molecular testing becomes increasingly essential for optimal NSCLC care, requiring careful consideration of how testing programs are implemented across diverse healthcare settings.